Menu Search
Equities

Procept Biorobotics Corp

PRCT:NMQ

Procept Biorobotics Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)99.07
  • Today's Change2.84 / 2.95%
  • Shares traded742.53k
  • 1 Year change+201.49%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Procept Biorobotics Corp had net income fall 21.51% from a loss of 87.15m to a larger loss of 105.90m despite a 81.55% increase in revenues from 75.01m to 136.19m.
Gross margin57.39%
Net profit margin-50.07%
Operating margin-53.27%
Return on assets-25.16%
Return on equity-37.02%
Return on investment-28.58%
More ▼

Cash flow in USDView more

In 2023, Procept Biorobotics Corp increased its cash reserves by 15.33%, or 34.59m. Cash Flow from Financing totalled 167.80m or 123.21% of revenues. In addition the company used 108.00m for operations while cash used for investing totalled 25.21m.
Cash flow per share-1.85
Price/Cash flow per share--
Book value per share4.64
Tangible book value per share4.63
More ▼

Balance sheet in USDView more

Procept Biorobotics Corp appears to have a strong balance sheet and has grown its cash reserves consistently over the last four years to total 257.22m.
Current ratio6.02
Quick ratio5.07
Total debt/total equity0.2132
Total debt/total capital0.1758
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.